All News
RA pts are at risk of pneumonia, & inflamed lung mucosa can produce RF/CCP. Are these linked via subclinical lung injury?
Seropos RA pts @BrighamWomens have double the pneumonia risk post-adjustment.
We're still learning more about RF...
@jeffsparks OP0111 #EULAR2020 @RheumNow https://t.co/C3CYpXABGc
David Liew drdavidliew ( View Tweet)
GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail.
Large Israeli database says there are links
(EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why?
OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah
David Liew drdavidliew ( View Tweet)
AAV/PAN and cancer: risk from meds has always been the question.
Interesting therefore that GPA/MPA pts accumulated incident cancer risk over time, whereas other AAV/PAN pts had risk early after dx...
Jo Tieu 🇦🇺@earlyARA @helenkeen73 @CatherineL_Hill OP0145 #EULAR2020 @RheumNow https://t.co/8ywycZuMHV
David Liew drdavidliew ( View Tweet)
Tenosynovitis is underrated in RA.
A nice reminder from an Argentinian group, who USS scanned 90 RA pts in clinical remission >3m and followed them for 12m. Subclinical synovitis did not predict flares, but subclinical tenosynovitis did (adj OR 9.8)
THU0119 #EULAR2020 @RheumNow https://t.co/kcle8qyQbI
David Liew drdavidliew ( View Tweet)
Physician global assessment in RA is a murky beast, which we should standardise better (especially interrater).
Portuguese cross-sectional (n = 392): SJC/CRP/HAQ/PGA did not fully explain it.
What are we capturing, and does it matter?
THU0111 #EULAR2020 @Janetbirdope @RheumNow https://t.co/krL2yFIl8a
David Liew drdavidliew ( View Tweet)
Do certain TNFi get more affected by obesity in RA? I have colleagues convinced infliximab is better for obese pts (weight-based dosing).
It actually seems obese RA pts might do as well as other RA pts w etanercept, but not w infliximab!
@DrMiniDey OP0220 #EULAR2020 @RheumNow https://t.co/EsaLTqINpd
David Liew drdavidliew ( View Tweet)
JAKi and VTE from @WHO VigiBase @UMCGlobalSafety
Why the difference between Europe and US?
There may be a class effect here (there may not be), but if we really want real-world answers we need effective systematic real-world data collection
OP0237 #EULAR2020 @RheumNow https://t.co/Bh2iLpGdXM
David Liew drdavidliew ( View Tweet)
RA isn't just a disease of joints & tendons: muscle is abnormal even at diagnosis. Changes throughout disease seen on MRI: T2, fatty infiltration, muscle volume all vary at different stages. Plenty more to understand/optimise! @LeedsBRC @DrAiLynTan OP0332 #EULAR2020 @RheumNow https://t.co/PwjLuZ1wcL https://t.co/QSYZALfi29
David Liew drdavidliew ( View Tweet)
I mean, the EULAR recommendations for management of early arthritis are tough:
"1. Patients presenting arthritis... should be referred to, and seen by, a rheumatologist, within 6 weeks after the onset of symptoms"
Does it matter though?
https://t.co/wJkVHQZqjs
David Liew drdavidliew ( View Tweet)
Outcome measures => Validity and reliability from @sofiaramiro82 #EULAR2020 @RheumNow https://t.co/M3XIDsTK39
Dr Philip Robinson philipcrobinson ( View Tweet)
MAINRITSAN3 RCT, RTX v PLBO in AAV
28mo relapse free survival ⬇️ RTX (96% vs 74%, NNT~4), majr (100% vs 87%, NNT~8)
1. Selected grp (all pts from MAINRITSAN2)
2. All pts had GC q3mos - IRL benefit could be bigger?
Strong data for RTX >2yrs in AAV
PDF: https://t.co/Mbrq7bFHk0 https://t.co/auKJ3QPKr0
Mike Putman EBRheum ( View Tweet)
Yet another NEGATIVE Trial in Hand OA. Add Hand OA to the list that Includes Scleroderma, Sjogrens and CRPS as untreatable diseases with large unmet needs! https://t.co/cMMqmeo19N
Dr. John Cush RheumNow ( View Tweet)
Anti-CD74 IgA antibodies are most sensitive and specific to identify young male axSpA patients, data from @XBaraliakos and others: Abstract FRI0312 #EULAR2020 @RheumNow https://t.co/yrevk8Wsiw https://t.co/kzcje2rRNa
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
ASAS modification of the Berlin algorithm and the duet algorithm for diagnosing axSpA : results from the screening in axSpA for psoriasis, iritis, and colitis cohort: Abstract FRI0298 #EULAR2020 @RheumNow https://t.co/BkG7c2riRb https://t.co/f63MsxWmd3
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Drug retention rates & treatment outcomes in 1,860 axSpA patients Rx with secukinumab in routine clinical practice in 13 European countries in the EuroSpA research collaboration network -> registry data drug retention rates THU0398 @RheumNow #EULAR2020 https://t.co/x3Y4tMetij https://t.co/DkUyIfyWwS
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
The Relative Diagnostic Utility of inflamm back pain criteria in inception cohort with PsO, Iritis, & Colitis Presenting With Undiagnosed Back Pain: All IBP criteria have poor diagnostic utility for dx of axSpA, esp in PsO Abs SAT0378 #EULAR2020 @RheumNow https://t.co/Y7sbtJtm3U https://t.co/P9q7uJozZ9
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Filgotinib was associated with significant reduction in SIJ erosion scores in axSpA: imaging data from the double-blind, randomized Tortuga trial #EULAR2020 @rheumnow THU0377 https://t.co/1b18Uyvo5j https://t.co/zBXCwGc0Q7
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
Integrated safety analysis of filgotinib treatment for RA from 7 clinical trials: 4,057 patients, VTE risk looks very reassuring #EULAR2020 @RheumNow https://t.co/Ld2tpu7UT5 https://t.co/sZqadeUTh8
Links:
Dr Philip Robinson philipcrobinson ( View Tweet)
The first randomized clinical trial of convalescent plasma in #COVID19, reported by Li et al in JAMA suggests that high titer antibody against #SARSCoV2 may have antiviral efficacy https://t.co/6YIib2GXGX
JAMA JAMA_current ( View Tweet)
Great talk on inflammasomes at #EULAR2020 by @dave_boucher: 4th June, 1:15pm, Ansell: Inflammasome activation in rheumatic diseases: mechanisms and perspectives for therapy @RheumNow https://t.co/HTWVxt4FMz
Dr Philip Robinson philipcrobinson ( View Tweet)